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Abstract
Multidrug-resistant (MDR) and carbapenem-resistant (CR) Gram-negative pathogens are becoming increasingly prevalent
around the globe. Polymyxins and tigecycline are among the few antibiotics available to treat infections with these bacteria
but little is known about the frequency of their use. We therefore aimed to estimate the parenteral use of these two drugs in
Veterans Affairs medical centers (VAMCs) and to describe the pathogens associated with their administration. For this
purpose we retrospectively analyzed barcode medication administration data of parenteral administrations of polymyxins
and tigecycline in 127 acute-care VAMCs between October 2005 and September 2010. Overall, polymyxin and tigecycline
use were relatively low at 0.8 days of therapy (DOT)/1000 patient days (PD) and 1.6 DOT/1000PD, respectively. Use varied
widely across facilities, but increased overall during the study period. Eight facilities accounted for three-quarters of all
polymyxin use. The same statistic for tigecycline use was twenty-six VAMCs. There were 1,081 MDR or CR isolates during 747
hospitalizations associated with polymyxin use (1.4/hospitalization). For tigecycline these number were slightly lower:
671 MDR or CR isolates during 500 hospitalizations (1.3/hospitalization) (p=0.06). An ecological correlation between the
two antibiotics and combined CR and MDR Gram-negative isolates per 1000PD during the study period was also observed
(Pearson’s correlation coefficient r=0.55 polymyxin, r=0.19 tigecycline). In summary, while polymyxin and tigecycline use is
low in most VAMCs, there has been an increase over the study period. Polymyxin use in particular is associated with the
presence of MDR Gram-negative pathogens and may be useful as a surveillance measure in the future.
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Introduction
In recent years, several studies have reported encouraging
trends for multidrug-resistant (MDR) Gram-positive pathogens. In
one such study, a decrease in health care-associated methicillin-
resistant Staphylococcus aureus (MRSA) infection rates was observed
after the implementation of a MRSA bundle in all Veterans Affairs
medical centers (VAMCs) in 2007. [1] Similar trends have been
reported from other settings in the United States and from other
countries, such as the United Kingdom and France. [2,3,4]
Unfortunately, these advances have been partly offset by the fact
that a series of resistance genes coding for broad-spectrum beta-
lactamases–NDM-1, KPC, VIM, OXA-48, CTX-M-15, and
AmpC, to name just a few–are increasingly found in Gram-
negative bacteria across the globe. [5,6]
These genes coding for enzymes capable of conveying resistance
to broad-spectrum cephalosporins and carbapenems are not only
harbored by typical nosocomial pathogens, but also by pathogens
associated with the community, such as Escherichia coli. [7] The
presence of extended-spectrum beta-lactamase (ESBL) genes in the
strain of E. coli that caused a recent outbreak of hemolytic-uremic
syndrome in Germany is a reminder that antimicrobial resistance
in Enterobacteriaceae is not a problem limited to hospitals. [8] In
addition, multiple resistance genes are often clustered on plasmids,
rendering their owners extensively or even pan-drug resistant.
[9,10] Carbapenem resistance is of particular concern since few
antibiotics are available to treat infections with carbapenem-
resistant (CR) organisms. [11]
This emerging resistance has led to a focus on antibiotics from
alternative classes. Tigecycline, an antibiotic structurally related to
tetracyclines, was approved in the United States in 2005 and
shows activity against MDR Gram-negative pathogens, with
a notable gap in coverage of Pseudomonas species. [12] Recent
randomized controlled trial data showing higher all-cause
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enthusiasm for this drug. [13,14,15] Increasing attention is being
paid to the polymyxins, a class of antibiotics that had fallen out of
favor with clinicians due to concerns about toxicity and un-
certainty about optimal dosing strategies. [16,17,18] Despite the
fact that the use of polymyxins or tigecycline probably indicates
the presence or suspicion of problematic pathogens, there are no
comprehensive data about the use of these antibiotics, nor which
pathogens motivate their use. The availability of comprehensive
antimicrobial prescribing and microbiology data from VAMCs
offers a unique opportunity to fill this gap in understanding both
an older and newer antimicrobial agent.
Methods
There are 152 VAMCs providing acute and long-term care
across the United States. To capture inpatient data, we included
records from acute medical, surgical, neurological, and intensive-
care units in our antibiotic and microbiologic analyses. We further
restricted the cohort to facilities with at least 10 operational acute-
care beds during fiscal years (FY) (October, 1- September, 30)
2006 through 2010, and those with barcode medication admin-
istration (BCMA) data available over the entire study period.
Antibiotic Use Data
We used nationwide, individual-level data drawn from the VA
Informatics and Computing Infrastructure (VINCI) for this study.
BCMA technology was introduced VA-wide in 2000 to improve
medication safety. [19] With each administered dose of medica-
tion, data regarding drug and route of administration are recorded
electronically with a time stamp. To detect missing data, we
assessed the completeness of the BCMA data set by comparing it
with electronic orders. We deemed antibiotic BCMA data to be
complete in a facility from the first month in which the difference
between antibiotic use in BCMA data and standard electronic
orders was less than 20% (based on at least one recorded order or
BCMA entry) for five commonly used index antibiotics (cipro-
floxacin, vancomycin, piperacillin/tazobactam, metronidazole,
and ceftriaxone). We used this cutoff because some medication
orders are written and cancelled before a single dose can be
administered. In addition it should be noted that a bar code
quality program to ensure 100 percent scan success rates has been
implemented VA-wide in 2006. BCMA data were used to assess
the use of parenteral polymyxins (polymyxin B and colistin/
colistimethate, which we will refer to collectively as ‘‘colistin’’) and
tigecycline. [9,10]
Antibiotic use was expressed in terms of ‘‘days of therapy’’
(DOT). One DOT was defined as the administration of a single
antibiotic on a given day independent of the number of doses, the
strength of the dose administered, or the route of administration.
[20] DOT were denominated by patient days using a midnight
census approach. As such, the discharge day was not counted in
the numerator or the denominator. We also denominated
antibiotic use by ‘‘hospitalizations’’ where at least one hospital
inpatient day fell within the study period.
Microbiology Data
The methods used to extract microbiology data from the VA
network have been previously described elsewhere with regard to
MRSA. [21] We used analogous methods to extract microbiology
data for Gram-negative pathogens. In brief, organisms and
susceptibilities were extracted into a relational structure from
semi-structured text documents using natural language processing
(NLP). All inpatient microbiology data between the 7th day before
and 1st day after the first day of polymyxin or tigecycline use were
also manually reviewed. Only the first unique isolate of a species
(defined by the susceptibility pattern) for each hospitalization was
analyzed. Isolates without at least one reported susceptibility and
cultures obtained in the outpatient setting were excluded. Multi-
drug resistance was defined as ‘‘acquired’’ non-susceptibility to at
least one agent in three or more antimicrobial categories according
to the definitions proposed by a joint initiative by the European
Centre for Disease Prevention and Control (ECDC) and the
Centers for Disease Control and Prevention (CDC). [22]
Carbapenem-resistance definitions were also pathogen-specific
and drawn from the same proposal. We were not able to apply the
proposed definitions for extensively drug-resistant (XDR) and pan-
drug resistant (PDR) bacteria due to the lack of standardization of
reported susceptibilities; however, we modified the definition of
XDR to be resistance in all reported drug classes except
polymyxins. Analyses of multi-drug resistance were restricted to
Enterobacteriaceae, Acinetobacter, and Pseudomonas species due to the
lack of comprehensive definitions for other Gram-negative
organisms.
We used descriptive statistics to describe antibiotic use and
microbiology data. All analyses were performed using STATA
version 11 (StataCorp. 2009. College Station, TX).
Ethics Statement
This study was approved by the Research Review Committee of
the VA Salt Lake City Health Care System and Institutional
Review Board of the University of Utah. As the study involved
retrospective review of existing medical record data with no
patient contact, the IRB approved and granted waiver of informed
consent to access medical records. All results are presented in
aggregate to protect the privacy and confidentiality of study
subjects.
Results
Of 152 VAMCs, 20 did not meet our acute-care services
criteria, 1 was excluded for less than 10 acute-care beds, and 4
were excluded for incomplete BCMA data. The remaining 127
VAMCs logged 2.42 million unique hospitalizations on the
included wards over the study period accounting for over 13.57
million patient days (table 1).
Table 1. Characteristics of the 127 hospitals October 2005
through September 2010.
Hospital Characteristics Count (%)
Hospitals with ICUs 121 (95.3)
University affiliated 115 (90.6)
VA region
1 West 24 (18.9%)
2 Central 36 (28.4%)
3 Southeast 40 (31.5%)
4 Northeast 27 (21.3%)
Value [IQR]
Average daily occupied acute Care Beds 53.0 [26.3–81.1]
Average daily occupied ICU Beds 8.0 [3.4–13.9]
doi:10.1371/journal.pone.0036649.t001
Polymyxin and Tigecycline Use in VA Hospitals
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There were 11,535 days of therapy (DOT) of polymyxins (0.1%
of overall DOT for systemic antibiotics) administered during 1,145
hospitalizations over the study period. Polymyxin B, which is part
of the national VA formulary, accounted for 63.7% (7,343 DOT)
of all IV polymyxin DOT (the remaining DOT were colistin). In
comparison, there were 21,886 DOT of tigecycline during 3,125
hospitalizations.
Tigecycline DOT rose more steeply than polymyxin DOT
during the five-year period of analysis (figure 1). From FY 2006,
the first full fiscal year of tigecycline approval, to FY 2010,
tigecycline use increased 4.2 fold. Polymyxin use peaked in FY
2009 then declined modestly in FY 2010.
The distribution of hospital polymyxin use across facilities was
more skewed than that of tigecycline use (figure 2). The facility
with the highest polymyxin use prescribed 53.9% of all polymyxin
DOT. Only 8 (6%) facilities accounted for 75% of polymyxin use.
In FY 2010, polymyxin DOT in the highest use facility were more
than four times greater than the polymyxin DOT in second
highest use facility (20.6 vs 4.9 DOT per 1000 PD). Overall, 54
hospitals used no polymyxins during the five year time frame. In
contrast, the facility with the highest tigecyline use accounted for
8.8% of tigecycline DOT. Twenty-six facilities (20%) accounted
for 75% of tigecycline DOT over the study period, while 22
hospitals did not use tigecycline at all.
Polymyxin and tigecycline use varied across different geo-
graphic regions. Yet, each region demonstrated an upward
temporal trend in polymyxin and tigecycline utilization (with the
exception of the Northeast where polymyxin prescribing was
relatively stable). The comparison of geographic regions was
dominated by the effect of an outlier effect. Excluding the highest
use facility, overall polymyxin prescribing was 0.7 DOT per 1000
PD in the northeastern region compared to 0.3, 0.3, and 0.4 DOT
per 1000 PD in the other three regions. Tigecycline use (again
excluding the outlier facility) was also highest in the Northeast at
2.9 DOT per 1000 PD.
Polymyxins were administered for a median of 7 days (IQR 4–
13, mean 10.1) and tigecycline for a median of 5 days (IQR 3–9,
mean 7.0) per hospitalization. In comparison, the individual
median number of days for any antibiotic therapy was 3 days (IQR
2–6) per hospitalization. 49.0% of all polymyxin DOT were
administered in intensive care units, while this was the case for
only 33.5% of tigecycline DOT.
While 86.8% of all antibiotic courses were started within the
first 2 days of admission, polymyxins were started a median of 15
days after the day admission (IQR 4–31) and only 14.8% of
polymyxin courses were started within the first 2 days. Tigecycline
was started earlier at a median of 4 days after the day admission
(IQR 1–12), and 37.1% of all courses were started within 2 days.
Patients receiving polymyxins received a median of 12 days (IQR
3–26) of antibiotic therapy before the first dose of polymyxins,
while patients receiving tigecycline had received a median of 3
days of antibiotics (IQR 0–10).
Polymyxins were administered mostly in combination with
other antibiotics (IV polymyxins were administered alone on only
16.3% of days). On average, 1.6 (SD 1.1) other antibiotics were
given concomitantly. Tigecycline was administered with polymyx-
ins on 7.1% of polymyxins days. For comparison tigecycline was
given with an average of 0.9 (SD 1.0) other antibiotics and
tigecycline was given alone on 44.5% of all tigecycline days.
Microbiology
There were 1,274 unique Gram-negative isolates recovered
between the 7th day before and the 2nd day after the first dose of
IV polymyxin each hospitalization. Of these, 1,081 isolates fulfilled
criteria for MDR or CR Enterobacteriaceae, Pseudomonas, or
Figure 1. Trends in the use of polymyxin and tigecycline in days of therapy (DOT) per 1000 patient days (PD) by fiscal year.
doi:10.1371/journal.pone.0036649.g001
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monas isolates. The resistant isolates were found among 747 unique
hospitalizations (65.2%) when polymyxins were used; no pathogen
was identified in 350 hospitalizations (30.6%) (the remainder
demonstrating pathogens not fulfilling MDR or CR criteria).
Pseudomonas aeruginosa (361; 33.4%), Klebsiella spp. (344; 31.8%),
Acinetobacter spp. (228; 21.1%), and Escherichia coli (49; 4.5%)
together accounted for most resistant isolates. Enterobacteriaceae
other than the organisms listed above made up an additional
9.2%. The most common culture site among resistant organisms
was sputum (table 2).
Using the same definitions as for polymyxins, there were 1,280
unique Gram-negative isolates for tigecycline (174 of which were
also found with concurrent polymyxin use). Of these, 671 met
criteria for MDR or CR Enterobacteriaceae, Pseudomonas,o r
Acinetobacter (figure 3). There were 70 Stenotrophomonas isolates. All of
the resistant isolates were found in 500 hospitalizations (16% of all
hospitalizations when tigecycline was used). There were 2,281
hospitalizations without pathogens. The remainder were non-
resistant isolates.
We also examined the ecological correlation between the two
antibiotics and combined CR and MDR Gram-negative isolates
per 1000 PD during the time period. Removing the extreme
outlier facility, the Pearson correlation coefficient was 0.55 for
polymyxin and 0.19 for tigecycline (figure 4).
Discussion
In this explorative study, we found 1) an increase in the use of
‘‘last-resort’’ antibiotics over the study period, 2) important
variation in the use of these antibiotics among facilities, and 3)
as expected, the frequent presence of MDR and/or CR Gram-
negative pathogens in patients treated with polymyxins.
We observed an increase in the use of polymyxins and
tigecycline during the study period, although the overall use is
still relatively low (0.3% of overall DOT for systemic antibiotics).
There are no comprehensive data about the use of ‘‘last-resort’’
antibiotics in US facilities, so direct comparisons over similar
geographic regions are difficult. Two recent studies describing
outbreaks of CR Klebsiella pneumoniae (Detroit 2009, Pittsburgh
2010) reported their ICU colistin use: 20.7 and 30.8 defined daily
doses (DDDs) per 1000 patient-days respectively. [23,24] Com-
parison with these data is difficult since they refer to outbreak
settings. In addition caution has to be applied when comparing
DDD to DOT, especially for drugs like polymyxins where there is
significant uncertainty about the optimal dosing strategy. While
the median antibiotic use density of polymyxin in VA ICUs was
2.1 DOT per 1,000 PD in ICUs that used at least one dose in 2010
there was one notable outlier at 57.3 DOT/1000 PD in FY 2010.
In general, relatively few facilities, concentrated primarily in the
Northeastern United States, contributed disproportionately to
overall use.
Tigecycline is frequently used in conjunction with polymyxins
and is often considered a ‘‘last-resort’’ antibiotic in its own right,
but it seems to be used very differently. Compared to
polymyxins, it appears to have been used more frequently in
empiric treatment regimens and more often as a single agent.
This is not surprising since tigecycline has been marketed for
a relatively broad-range of indications, including community-
acquired pneumonia and Gram-positive pathogens. We are not
aware of any publicly available data on tigecycline use with
which to compare; it will be interesting to follow its use in the
Figure 2. Dot plot of tigecycline and polymyxin use by facility in DOT per 1000 PD in fiscal year 2010. Each dot represents one
facility (n=127).
doi:10.1371/journal.pone.0036649.g002
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infections. [13,18].
The microbiology of Gram-negative isolates observed around
the initiation of polymyxins demonstrated that this drug class was
mainly used to treat resistant pathogens. There was a moderate
Figure 3. Pathogens isolated. a) when polymyxins (1,145 hospitalizations) or b) tigecycline (3,125 hospitalizations) were used. Only Acinetobacter
spp., E. coli, Klebsiella spp. and P. aeruginosa* are included MDR: multi-drug resistance (non-susceptibility to .=3 drug classes) CR: carbapenem
resistance (non-susceptibility to carbapenems; ertapenem not considered for non-fermenters) XDR: non-susceptibility to all tested classes except to
polymyxins (definitions of MDR, CR and XDR adapted from reference [22]) *In 206/225 cases where tigecycline was given and a Pseudomonas was
isolated, the patient had at least one anti-pseudomonal spectrum agent (definition of anti-pseudomonal activity based on reference [22]).
doi:10.1371/journal.pone.0036649.g003
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drug resistant Gram-negative isolates over the study period.
Although there is generally a two-way causal relationship between
antibiotics and resistance, it seems unlikely that low-levels of
polymyxin use greatly influence resistance to other antibiotic
classes. We therefore surmise that the observed association
between resistance and polymyxin use largely reflects the former
driving the latter. Despite tigecycline being used more often than
polymyxins, there were fewer resistant Gram-negative isolates
associated with its use.
We were surprised to find that 30% of hospitalizations when
polymyxins were used did not reveal any pathogens where
susceptibility testing was performed. Possible explanations are
that systemic polymyxins are often administered after long courses
Table 2. Culture sample types by resistant (MDR, CR or XDR) pathogen.
POLYMYXINS
Culture site
Acinetobacter spp.
# isolates (%) E. coli # isolates (%) Klebsiella spp. # isolates (%) P. aeruginosa # isolates (%)
Sputum 122 (53.5%) 13 (26.5%) 138 (40.1%) 201 (55.7%)
Urine 17 (7.5%) 13 (26.5%) 84 (24.4%) 73 (20.2%)
Blood 55 (24.1%) 7 (14.3%) 74 (21.5%) 38 (10.5%)
Other 34 (14.9%) 16 (32.7%) 48 (14.0%) 49 (13.6%)
TIGECYCLINE
Culture site Acinetobacter spp. # isolates
(%)
E. coli # isolates (%) Klebsiella spp. # isolates (%) P. aeruginosa # isolates (%)
Sputum 93 (50.8%) 29 (22.5%) 54 (31.2%) 49 (50.0%)
Other 39 (21.3%) 64 (49.6%) 38 (22.0%) 24 (24.5%)
Blood 35 (19.1%) 12 (9.3%) 32 (18.5%) 10 (10.2%)
Urine 16 (8.7%) 24 (18.6%) 49 (28.3%) 15 (15.3%)
Only isolates recovered between the 7th day before and the 1st day after the first day of polymyxin or tigecycline use were included.
doi:10.1371/journal.pone.0036649.t002
Figure 4. Correlation between polymyxin/tigecycline use in days of therapy (DOT) per 1000 patient days (PD) and MDR & CR Gram-
negative pathogens per 1000 PD (aggregated over the entire study period). Extreme polymyxin use outlier excluded.
doi:10.1371/journal.pone.0036649.g004
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represents either an empiric escalation in patients failing therapy
or empiric coverage of pathogens isolated more than a week prior
to polymyxin initiation or from outside the VA. Non-fermenters
were the most frequent pathogens and most isolates of P. aeruginosa
and Acinetobacter spp. were MDR and CR; however, Klebsiella
species were nearly as common as P. aeruginosa and also
demonstrated frequent carbapenem and extensive-drug resistance.
Even though data on strain typing or carbapenem resistance
mechanisms were not available, KPC enzymes are known to be
present in the VA system. [25,26] Although tigecycline was
sometimes used in association with Pseudomonas isolates, it should
be noted that tigecycline is not active against this pathogen (idem
for Proteus species) and in nearly all those case patient also received
an anti-pseudomonal agent.
There is evidence of increasing carbapenem resistance through-
out the United States. Thirty-eight states have reported CR
Enterobacteriaceae (CRE) cases to the CDC in 2010 and some
data indicate a dramatic rise in CRE in recent years. Given the
sharing of patients between VAMCs, academic, and community
hospitals, it is unlikely that VA trends will be independent from
national trends.
Our study has several limitations. Although BCMA likely
represents one of the most accurate ways to capture patient-level
medication administration data and compliance with BCMA
standards is regularly monitored within the VA system, we cannot
be certain that all delivered doses were captured, which would
underestimate antibiotic use. Similarly, since carbapenem re-
sistance was difficult to identify in Enterobacteriaceae before
revision of the Clinical and Laboratory Standards Institute (CLSI)
carbapenem susceptibility breakpoints in mid-2010, and many
facilities did not routinely test ertapenem in Enterobacteriaceae,
we are likely to have underestimated carbapenem resistance in this
family. [27] In addition, antibiotic susceptibility reporting is not
standardized among VAMCs and some facilities routinely
suppress antibiotic susceptibilities for certain organisms, potentially
leading to an underestimation of carbapenem resistance. Multi-
drug resistance could also be biased simply from which
susceptibilities laboratories chose to report. On the other hand,
providers likely order cultures more frequently when they suspect
resistance, thereby increasing the sampling of both colonizing and
infecting organisms and biasing resistance estimates upward. Since
the molecular mechanism of carbapenem resistance was not
routinely determined, we were also unable to analyze the
molecular epidemiology of carbapenem resistance in the VA
system. Our approach to analyze microbiology culture within the
7th day before and 1st day after the first day of polymyxin or
tigecycline use has not been formally validated. Electronic
algorithms sometimes use, however, similar temporal rules. [28]
Finally, the VA patient population may not be representative of
other US hospitals and the findings of this study may thus not be
generalizable to the entire United States.
To our knowledge this is the first study examining the use of
‘‘last-resort’’ antibiotics and the microbiology associated with their
use in a large health-care system with detailed patient-level
electronic data over several years. The total amount of polymyxin
and tigecycline use is still relatively low in most VAMCs, but there
has been an increase in the use of these drugs during the study
period. Not surprisingly, our analysis shows polymyxin use is
associated with MDR Gram-negative pathogens. The absence of
antibiotics that are as effective and safe as the beta-lactams to treat
infections with multi-resistant Gram-negative pathogens is a par-
ticular cause for concern. The Infectious Disease Society of
America (IDSA) 106‘20 initiative has called for the development
of 10 new systemic antibacterial drugs by 2020 by facilitating the
antibiotic approval pathway and creating incentives for drug
manufacturers to develop new antibiotics. [29] This issue is also
currently under review in the US congress (Generating Antibiotic
Incentives Now (GAIN) Act). It remains to be seen if this goal can
be met. In the meantime, strict infection control practice,
combined with the judicious use of antibiotics in all settings
(including the ambulatory care and veterinary sector), are our best
weapons to address this threat. Electronic biosurveillance systems,
more in-depth analyses about the characteristics and clinical
outcomes of the patient group described in this study, and
additional insight into the mechanisms of resistant pathogens
transmission will be invaluable in this endeavor.
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